 |
- Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance
MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announce the signing of a contract providing support to the WFH Humanitarian Aid Program in the form of medicine donations and financial assistance for up to 5 years. This is the second renewal of the collaboration, which has been in place for more than ten years and demonstrates the partners' commitment to providing the necessary care and resources for people with hemophilia around the world.
The commitment includes the donation of up to 100 million international units (IU) of factor therapy per year that will be distributed by the WFH Humanitarian Aid Program worldwide to developing countries. This will enable the WFH to deliver aid to people with inherited bleeding disorders across the globe.
The new signing comes as Sanofi and Sobi celebrate the tenth anniversary of answering the WFH call to action to support the global inherited bleeding disorders community through the donation of treatment products and financial aid. Between 2014 and 2024, Sanofi and Sobi provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders.
Alaa Hamed
Global Head of Medical Affairs, Rare Diseases, Sanofi
"Building on the legacy of the original ten-year, one billion IU commitment, this new agreement reaffirms Sanofi and Sobi's dedication to creating a predictable, sustainable program that addresses unmet needs and advances the standard of care for hemophilia worldwide. Over the past decade, these contributions have expanded treatment availability and transformed patient outcomes. We are proud to leverage the Foundation S expertise and continue providing essential treatments and with this renewal ensuring improvement to the quality of life for thousands of individuals in developing countries for years to come."
Lydia Abad-Franch
Head of R&D and Chief Medical Officer, Sobi
"We are immensely proud to continue our contributions to the Humanitarian Aid Program of the World Federation of Hemophilia (WFH). Since the initial pledge, over 22,000 people with hemophilia have been treated with factor donated by Sobi and Sanofi. We are thrilled to continue our partnership with the WFH and look forward to the positive impact it will have on the lives of those affected by inherited bleeding disorders."
Cesar Garrido
President, World Federation of Hemophilia
"The contributions of Sanofi and Sobi to the WFH Humanitarian Aid Program can't be overstated — and especially in the last ten years after they answered the WFH call to action. This new five-year contract will continue that legacy of support for the global inherited bleeding disorders community, and it will help us get closer to our shared vision of Treatment for All."
Mark Skinner
Board Member, World Federation of Hemophilia, USA
"The WFH Humanitarian Aid program is an extraordinary example of collaboration. The life-changing impact of this program is a testament to what can be achieved by working together with our industry partners. The visionary leadership of Sobi and Sanofi's Foundation S has provided inspiration for others in industry, hope for patients and their families, and elevated capacity of health care professionals around the world."
About the World Federation of Hemophilia
The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide tools they need to identify, support and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals. The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor.
Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world.
To find out more about the WFH, please visit www.wfh.org.
About WFH USA
WFH USA furthers the mission of the WFH in the U.S. by deepening engagement of American citizens with our global vision of Treatment for All and raising funds to bring that vision to life. By working with the World Federation of Hemophilia, we help transform communities by equipping and empowering WFH national member organizations (NMOs) and healthcare providers with the knowledge and tools they need to identify, support and treat people living with bleeding disorders around the world. To find out more about WFH USA, please visit wfh.org/usa.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About Foundation S – The Sanofi Collective
Foundation S strives to create healthier futures for generations to come. We are driven by a singular purpose: to improve the lives of vulnerable populations by catalyzing community–based solutions, expanding access to medicines, and mobilizing collective action.
About Sobi
Sobi® is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Media contact: Neha Suchak, Director, Marketing & Communications, nsuchak@wfh.org, +1 514-875-7944, #2857, www.wfh.org
- Up to five-year contract extension to support the WFH Humanitarian Aid Program with medicine donations and financial assistance
MONTREAL, April 25, 2025 /PRNewswire/ -- The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation S, and Sobi, announce the signing of a contract providing support to the WFH Humanitarian Aid Program in the form of medicine donations and financial assistance for up to 5 years. This is the second renewal of the collaboration, which has been in place for more than ten years and demonstrates the partners' commitment to providing the necessary care and resources for people with hemophilia around the world.
The commitment includes the donation of up to 100 million international units (IU) of factor therapy per year that will be distributed by the WFH Humanitarian Aid Program worldwide to developing countries. This will enable the WFH to deliver aid to people with inherited bleeding disorders across the globe.
The new signing comes as Sanofi and Sobi celebrate the tenth anniversary of answering the WFH call to action to support the global inherited bleeding disorders community through the donation of treatment products and financial aid. Between 2014 and 2024, Sanofi and Sobi provided one billion IUs of treatment product, enabling the treatment of 22,219 people with inherited bleeding disorders.
Alaa Hamed
Global Head of Medical Affairs, Rare Diseases, Sanofi
"Building on the legacy of the original ten-year, one billion IU commitment, this new agreement reaffirms Sanofi and Sobi's dedication to creating a predictable, sustainable program that addresses unmet needs and advances the standard of care for hemophilia worldwide. Over the past decade, these contributions have expanded treatment availability and transformed patient outcomes. We are proud to leverage the Foundation S expertise and continue providing essential treatments and with this renewal ensuring improvement to the quality of life for thousands of individuals in developing countries for years to come."
Lydia Abad-Franch
Head of R&D and Chief Medical Officer, Sobi
"We are immensely proud to continue our contributions to the Humanitarian Aid Program of the World Federation of Hemophilia (WFH). Since the initial pledge, over 22,000 people with hemophilia have been treated with factor donated by Sobi and Sanofi. We are thrilled to continue our partnership with the WFH and look forward to the positive impact it will have on the lives of those affected by inherited bleeding disorders."
Cesar Garrido
President, World Federation of Hemophilia
"The contributions of Sanofi and Sobi to the WFH Humanitarian Aid Program can't be overstated — and especially in the last ten years after they answered the WFH call to action. This new five-year contract will continue that legacy of support for the global inherited bleeding disorders community, and it will help us get closer to our shared vision of Treatment for All."
Mark Skinner
Board Member, World Federation of Hemophilia, USA
"The WFH Humanitarian Aid program is an extraordinary example of collaboration. The life-changing impact of this program is a testament to what can be achieved by working together with our industry partners. The visionary leadership of Sobi and Sanofi's Foundation S has provided inspiration for others in industry, hope for patients and their families, and elevated capacity of health care professionals around the world."
About the World Federation of Hemophilia
The World Federation of Hemophilia (WFH) is a non-profit organization dedicated to improving and sustaining care for people with inherited bleeding disorders around the world. At the WFH, national member organizations (NMOs) and health care professionals (HCPs) work together to provide care for people with inherited bleeding disorders around the world. We partner with governments and hemophilia treatment centres to enhance knowledge through training and provide tools they need to identify, support and treat people living with bleeding disorders in their communities, while promoting global advocacy and collaboration to achieve our common goals. The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi and Sobi, our Founding Visionary Contributors; Bayer, CSL Behring and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and Takeda, our Contributor.
Our vision of Treatment for All is for a world where all people with inherited bleeding disorders have access to care, regardless of their type of bleeding disorder, gender, or where they live. Our mission is to improve and sustain care for people with inherited bleeding disorders around the world.
To find out more about the WFH, please visit www.wfh.org.
About WFH USA
WFH USA furthers the mission of the WFH in the U.S. by deepening engagement of American citizens with our global vision of Treatment for All and raising funds to bring that vision to life. By working with the World Federation of Hemophilia, we help transform communities by equipping and empowering WFH national member organizations (NMOs) and healthcare providers with the knowledge and tools they need to identify, support and treat people living with bleeding disorders around the world. To find out more about WFH USA, please visit wfh.org/usa.
About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people's lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY
About Foundation S – The Sanofi Collective
Foundation S strives to create healthier futures for generations to come. We are driven by a singular purpose: to improve the lives of vulnerable populations by catalyzing community–based solutions, expanding access to medicines, and mobilizing collective action.
About Sobi
Sobi® is a global biopharma company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of haematology, immunology and specialty care, Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.
Media contact: Neha Suchak, Director, Marketing & Communications, nsuchak@wfh.org, +1 514-875-7944, #2857, www.wfh.org
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Sanofi and Sobi extend their partnership with the World Federation of Hemophilia Humanitarian Aid Program
|
Introducing Vibe Testing for the Age of Infinite Code: As Agentic AI transforms software development, TestMu AI introduces autonomous agents to ensure quality keeps pace with infinite code, powering 1.5+ billion tests annually across 18,000+ enterprises.
SAN FRANCISCO and NOIDA, India, Jan. 12, 2026 /PRNewswire/ -- LambdaTest, the AI-native, agentic quality engineering platform, today announced its rebrand to TestMu AI, marking a bold step forward in its evolution from a cloud testing platform to the world's first full-stack Agentic AI Quality Engineering platform.
The transformation addresses a critical inflection point in software development: as AI generates code at unprecedented rates, traditional testing creates a bottleneck. Quality Engineering teams need intelligent systems that can reason about change, observe failures, and adapt continuously.
As TestMu AI, the organization is expanding its platform to support the next generation of software builders, including 'vibe coders.' Their AI agents allow developers to 'vibe test' and move at the speed of thought, and ensure that vibe-coded apps are not only of high quality but are also reliable when they come in front of customers.
This shift reflects the company's average 110% year-on-year growth over the last 2 years. To date, the platform has executed billions of tests for 18,000+ enterprise customers, including Microsoft, OpenAI, NVIDIA, Vimeo, Dunlem across 90+ countries.
Founded in 2018, LambdaTest rapidly became one of the most trusted names in cloud-based test orchestration and execution. They built a scalable, high-performance test cloud that removed flakiness, improved developer feedback loops, and drastically accelerated release velocity.
In 2022, the company began a deep transformation, moving deep into agentic AI across its products and workflows to empower autonomous, intelligent quality engineering at scale. Today, TestMu AI's AI-Agentic unified platform powers end-to-end quality engineering for over 2.8 million developers and testers worldwide, helping teams ship faster and build with confidence.
"AI is fundamentally changing how software is built and shipped," said Asad Khan, CEO and Co-Founder of TestMu AI (Formerly LambdaTest). "Development cycles that once took weeks now take hours. But speed without quality is chaos. We recognized that testing needed to evolve from brittle, high-maintenance automations to intelligent context-driven agents that understand change and act on it autonomously. We have evolved from an execution cloud into an active, intelligent partner in the software testing lifecycle. With billions of tests running on our platform, we are now delivering experiences where human ingenuity and machine intelligence combine to make quality engineering effortlessly powerful."
TestMu AI has rearchitected its platform to be AI-native, deploying autonomous AI Agents to plan, author, execute, and analyze software quality with minimal manual intervention. The platform now delivers:
- Autonomous AI Agents for Testing: Plan, author, and evolve end-to-end tests using company-wide context or simple natural language prompts. Users can now test every layer of the database, API, UI, performance, and more.
- Agentic AI Test Cloud: A scalable and unified test execution cloud to run any type of test at any scale, including visual regression, accessibility, API, and performance testing, web and mobile, to custom enterprise environments.
The name 'TestMu' was adopted directly from its community. Since 2022, the TestMu Conference has served as the industry's primary forum for advancements in AI and quality engineering.
By adopting this name, the company is signaling that the community is the core of the organization, infusing the spirit of that open, collaborative conference into the platform itself.
"Our community recognized the spirit of TestMu long before this announcement," Khan added. "TestMu represents a thriving community, a shared craft, and the future of quality engineering."
The company was recently recognized in the 2025 Gartner® Magic Quadrant™ for AI-Augmented Software Testing Tools report and in The Forrester Wave™: Autonomous Testing Platforms 2025 report.
"Our journey has mirrored the evolution of software testing itself," said Mudit Singh, Co-Founder and Head of Marketing, TestMu AI. "We began by building the 'Perfect Cloud for the Cloud Era,' solving pain points related to scalable infrastructure, and helped start the industry's one of the earliest conversations around AI in testing through the TestMu Conference. Today, we are entering a new phase, where agentic AI enables autonomous, end-to-end quality engineering. TestMu AI represents this shift: a forward-looking identity built for an AI-native future, while staying deeply rooted in our ecosystem, our community, and our relentless commitment to quality."
Looking ahead, TestMu AI's roadmap includes fully autonomous AI agents, agent-to-agent testing, evaluation of AI systems by AI agents, and deep integration with codebases and developer workflows, positioning quality engineering as a continuously learning, self-governing layer of modern software development.
For more information, visit: https://www.testmu.ai
About TestMu AI
TestMu AI (Formerly LambdaTest) is a Full-Stack Agentic AI Quality Engineering platform that empowers teams to test intelligently and ship faster. Engineered for scale, it offers end-to-end AI agents to plan, author, execute, and analyze software quality. AI-native by design, the platform enables testing of web, mobile, and enterprise applications at any scale across real devices, real browsers, and custom real-world environments.
Introducing Vibe Testing for the Age of Infinite Code: As Agentic AI transforms software development, TestMu AI introduces autonomous agents to ensure quality keeps pace with infinite code, powering 1.5+ billion tests annually across 18,000+ enterprises.
SAN FRANCISCO and NOIDA, India, Jan. 12, 2026 /PRNewswire/ -- LambdaTest, the AI-native, agentic quality engineering platform, today announced its rebrand to TestMu AI, marking a bold step forward in its evolution from a cloud testing platform to the world's first full-stack Agentic AI Quality Engineering platform.
The transformation addresses a critical inflection point in software development: as AI generates code at unprecedented rates, traditional testing creates a bottleneck. Quality Engineering teams need intelligent systems that can reason about change, observe failures, and adapt continuously.
As TestMu AI, the organization is expanding its platform to support the next generation of software builders, including 'vibe coders.' Their AI agents allow developers to 'vibe test' and move at the speed of thought, and ensure that vibe-coded apps are not only of high quality but are also reliable when they come in front of customers.
This shift reflects the company's average 110% year-on-year growth over the last 2 years. To date, the platform has executed billions of tests for 18,000+ enterprise customers, including Microsoft, OpenAI, NVIDIA, Vimeo, Dunlem across 90+ countries.
Founded in 2018, LambdaTest rapidly became one of the most trusted names in cloud-based test orchestration and execution. They built a scalable, high-performance test cloud that removed flakiness, improved developer feedback loops, and drastically accelerated release velocity.
In 2022, the company began a deep transformation, moving deep into agentic AI across its products and workflows to empower autonomous, intelligent quality engineering at scale. Today, TestMu AI's AI-Agentic unified platform powers end-to-end quality engineering for over 2.8 million developers and testers worldwide, helping teams ship faster and build with confidence.
"AI is fundamentally changing how software is built and shipped," said Asad Khan, CEO and Co-Founder of TestMu AI (Formerly LambdaTest). "Development cycles that once took weeks now take hours. But speed without quality is chaos. We recognized that testing needed to evolve from brittle, high-maintenance automations to intelligent context-driven agents that understand change and act on it autonomously. We have evolved from an execution cloud into an active, intelligent partner in the software testing lifecycle. With billions of tests running on our platform, we are now delivering experiences where human ingenuity and machine intelligence combine to make quality engineering effortlessly powerful."
TestMu AI has rearchitected its platform to be AI-native, deploying autonomous AI Agents to plan, author, execute, and analyze software quality with minimal manual intervention. The platform now delivers:
- Autonomous AI Agents for Testing: Plan, author, and evolve end-to-end tests using company-wide context or simple natural language prompts. Users can now test every layer of the database, API, UI, performance, and more.
- Agentic AI Test Cloud: A scalable and unified test execution cloud to run any type of test at any scale, including visual regression, accessibility, API, and performance testing, web and mobile, to custom enterprise environments.
The name 'TestMu' was adopted directly from its community. Since 2022, the TestMu Conference has served as the industry's primary forum for advancements in AI and quality engineering.
By adopting this name, the company is signaling that the community is the core of the organization, infusing the spirit of that open, collaborative conference into the platform itself.
"Our community recognized the spirit of TestMu long before this announcement," Khan added. "TestMu represents a thriving community, a shared craft, and the future of quality engineering."
The company was recently recognized in the 2025 Gartner® Magic Quadrant™ for AI-Augmented Software Testing Tools report and in The Forrester Wave™: Autonomous Testing Platforms 2025 report.
"Our journey has mirrored the evolution of software testing itself," said Mudit Singh, Co-Founder and Head of Marketing, TestMu AI. "We began by building the 'Perfect Cloud for the Cloud Era,' solving pain points related to scalable infrastructure, and helped start the industry's one of the earliest conversations around AI in testing through the TestMu Conference. Today, we are entering a new phase, where agentic AI enables autonomous, end-to-end quality engineering. TestMu AI represents this shift: a forward-looking identity built for an AI-native future, while staying deeply rooted in our ecosystem, our community, and our relentless commitment to quality."
Looking ahead, TestMu AI's roadmap includes fully autonomous AI agents, agent-to-agent testing, evaluation of AI systems by AI agents, and deep integration with codebases and developer workflows, positioning quality engineering as a continuously learning, self-governing layer of modern software development.
For more information, visit: https://www.testmu.ai
About TestMu AI
TestMu AI (Formerly LambdaTest) is a Full-Stack Agentic AI Quality Engineering platform that empowers teams to test intelligently and ship faster. Engineered for scale, it offers end-to-end AI agents to plan, author, execute, and analyze software quality. AI-native by design, the platform enables testing of web, mobile, and enterprise applications at any scale across real devices, real browsers, and custom real-world environments.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
LambdaTest Rebrands to TestMu AI, the World's First Agentic Quality Engineering Platform for Fully Autonomous Testing
